$GILD,...Gilead inks collaboration deal for Anthrax and Ebola vaccines
Nova Scotia-based Immunovaccine and Gilead Sciences (GILD -0.7%) establish a collaboration to develop and commercialize vaccines for Anthrax and Ebola based on the former's DepoVax adjuvanting platform. The main value proposition of the products is total immunity with a single dose.
Under the terms of the agreement, Immunovaccine grants Gilead an exclusive license for the research, development, manufacture and commercialization of DPX-Anthrax and DPX-Ebola for therapeutic uses in all indications in the U.S., Canada and select international markets. Gilead will pay Immunovaccine an upfront cash fee of $40M, over $100M in development milestones, $200M upon FDA approval and tiered double-digit royalties on commercial sales.
The FDA has designated both vaccines for Fast Track review and approved the start of Phase 1 trials.
invest at your own risk, based on your own due diligence, at your own risk tolerance
